Abcellera Biologics Inc - Asset Resilience Ratio
Abcellera Biologics Inc (ABCL) has an Asset Resilience Ratio of 32.72% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ABCL capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Abcellera Biologics Inc's Asset Resilience Ratio has changed over time. See Abcellera Biologics Inc (ABCL) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Abcellera Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABCL market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $427.67 Million | 32.72% |
| Total Liquid Assets | $427.67 Million | 32.72% |
Asset Resilience Insights
- Very High Liquidity: Abcellera Biologics Inc maintains exceptional liquid asset reserves at 32.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abcellera Biologics Inc Industry Peers by Asset Resilience Ratio
Compare Abcellera Biologics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Abcellera Biologics Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Abcellera Biologics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 29.87% | $405.31 Million | $1.36 Billion | -4.62pp |
| 2024-12-31 | 34.49% | $469.29 Million | $1.36 Billion | -7.66pp |
| 2023-12-31 | 42.15% | $627.26 Million | $1.49 Billion | +9.71pp |
| 2022-12-31 | 32.45% | $499.95 Million | $1.54 Billion | +13.73pp |
| 2021-12-31 | 18.72% | $246.84 Million | $1.32 Billion | -40.36pp |
| 2020-12-31 | 59.08% | $594.12 Million | $1.01 Billion | -- |
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more